Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 3,900 trials

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Metastatic Prostate Cancer: JNJ-78278343 Treatment Study

We are testing a new T-cell redirecting agent combined with other therapies for men with metastatic prostate cancer. The study aims to see if this combination can improve treatment results.

Metastatic Prostate Cancer>2 yearsSafety phase (I)OncologyUrology

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Asymptomatic Heart Failure: TREASURE Trial

We are studying whether an ACE inhibitor can improve heart health in women with asymptomatic heart failure compared to usual care. The trial also looks at its effects on heart function, metabolic health, and quality of life.

Subclinical Heart Failure>2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Advanced Melanoma: Lifileucel with Pembrolizumab

We are investigating whether a new treatment combining lifileucel with pembrolizumab is more effective than pembrolizumab alone for patients with untreated, advanced melanoma. The study aims to assess both effectiveness and safety.

MelanomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Mucopolysaccharidosis Type II: JR-141 Treatment Study

We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.

Mucopolysaccharidosis IIHunter Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurologyPediatrics

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

CAR123 T Cell Therapy for Blood Cancers

We are testing a new T cell treatment for patients with relapsed or refractory hematologic malignancies. The goal is to see if it can improve outcomes for those who have not responded to other therapies.

Relapsed/Refractory Blood CancersSafety phase (I)HematologyOncology

Fremanezumab for Pain in Complex Regional Pain Syndrome

We are studying whether fremanezumab can reduce pain in patients with Complex Regional Pain Syndrome compared to a placebo. The trial also examines how this treatment affects disease symptoms and function.

Complex Regional Pain Syndrome≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

Advanced Solid Tumors: RO7589831 and Pembrolizumab

We are testing a new treatment combining RO7589831 with Pembrolizumab for people with advanced solid tumors. This study aims to understand how effective this combination may be in managing their condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

ANCA-Associated Vasculitis: Avacopan Study

We are testing the long-term safety and effectiveness of Avacopan for people with ANCA-associated vasculitis. The study will also look at how it affects remission and overall quality of life.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineRheumatology

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

PDA Treatment in Premature Infants: Acetaminophen and Ibuprofen Study

We are studying whether combining acetaminophen with ibuprofen helps extremely premature infants with a heart condition. The goal is to see if this combination reduces serious complications compared to ibuprofen alone.

Patent Ductus Arteriosus≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyPediatrics

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Recurrent Miscarriages: PREMI Trial on Prednisolone

We are studying whether prednisolone can help women with unexplained recurrent miscarriages achieve a live birth. The trial compares this treatment to a placebo and looks at pregnancy outcomes and safety.

Recurrent Miscarriages1-2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine